Novartis AG
NVSNYSEPharmaceutical PreparationsFiscal year ends December 31Also trades as NVSEF
$160.79−0.31 (-0.19%)
Close on Oct 30, 2026Market cap $306.81BP/E 22.5Yield –
Novartis Kesimpta (ofatumumab by Year
Kesimpta (ofatumumab — self-administered B-cell antibody therapy for relapsing multiple sclerosis RMS) ($M)
Novartis Kesimpta (ofatumumab: $4,426M in FY2025, up 37.3% from a year earlier.
Latest, FY2025
4,426
Period ended Dec 31, 2025
Change on a year earlier
+37.3%
3,224 in FY2024
History
6 years
Since FY2020
Sources
5
Documents cited below
Where the FY2025 figure comes from
“|| Kesimpta | 4 426 | 3 224 | 37 | 36”
Source: Novartis Form 6-K (0001114448-26-000007) ↗
Reported in Form 6-K & Form 20-F.
Annual history
Hover a value to see the sentence it was read from; calculated values show their formula
| Period | Ended | Kesimpta (ofatumumab — self-administered B-cell antibody therapy for relapsing multiple sclerosis RMS) ($M) | Year on year | Source |
|---|---|---|---|---|
| FY2025 | Dec 31, 2025 | 4,426 | +37.3% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2024 | Dec 31, 2024 | 3,224 | +48.5% | Novartis Form 6-K (0001114448-26-000007) ↗ |
| FY2023 | Dec 31, 2023 | 2,171 | +98.8% | Novartis Form 6-K (0001370368-25-000007) ↗ |
| FY2022 | Dec 31, 2022 | 1,092 | +193.5% | Novartis Form 6-K (0001370368-24-000007) ↗ |
| FY2021 | Dec 31, 2021 | 372 | +2,380.0% | Novartis Form 6-K (0001370368-23-000008) ↗ |
| FY2020 | Dec 31, 2020 | 15 | – | Novartis Form 6-K (0001370368-21-000008) ↗ |
Breakdown
What makes up kesimpta (ofatumumab
Cite this data
StockData. (2026). Novartis Kesimpta (ofatumumab ($M), annual FY2020–FY2025 [Data set]. Compiled from Novartis SEC filings and investor materials. https://stockdatahq.com/stocks/nvs/kpis/brand-kesimpta
See every metric in the Novartis KPI table. Data updated Nov 2, 2026.